Continuation and maintenance treatment of major depression with the monoamine oxidase inhibitor phenelzine: a double-blind placebo-controlled discontinuation study
by
Robinson DS, Lerfald SC, Bennett B, Laux D,
Devereaux E, Kayser A, Corcella J, Albright D
Bristol-Myers Squibb Company,
Wallingford, CT 06492.
Psychopharmacol Bull 1991; 27(1):31-9

ABSTRACT

Long-term treatment with antidepressant drugs has received little attention until recently. A study is reported comparing the effectiveness of maintenance treatment with phenelzine in responding major depression patients. If they responded initially to nonblind phenelzine treatment and sustained remission for 16 weeks, patients were randomized to 2-year double-blind treatment with phenelzine 60 mg/day, phenelzine 45 mg/day, or placebo. Both doses of phenelzine were significantly better than placebo in preventing relapse of depression. Phenelzine 45 mg/day may be an optimal maintenance dose for many patients.

MAO
RIMAs
MAOIs
Phenelzine
Brofaromine
Befloxatone
Moclobemide
Isocarboxazid
Tranylcypromine
Phenelzine: structure
Phenelzine and GABA
Phenelzine versus imipramine
Phenelzine (Nardil) v tranylcypromine (Parnate)
Phenelzine (Nardil): prescribing information (PDF)

Refs
HOME
HedWeb
Future Opioids
BLTC Research
Paradise-Engineering
Utopian Pharmacology
The Hedonistic Imperative
When Is It Best To Take Crack Cocaine?

The Good Drug Guide
The Responsible Parent's Guide
To Healthy Mood Boosters For All The Family